Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

Under Armour Inc. Cl C 1.89% $2.96B Under Armour Inc. Cl A 1.68% $2.96B ...